Mylan teams up with Revance on biosimilar for Botox

NEW YORK (Reuters) – Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc’s blockbuster Botox wrinkle treatment.

Source: Reuters Medical News